Eevia Health Plc ("Eevia" or "The Company"), a leading health ingredient manufacturer from Finland, today announces that it has entered a multi-year sales agreement. The sales agreement is with a Finnish customer to supply a specialty protein and fiber plant extract with excellent nutritional values and versatile product applications for the global nutraceutical market.
Eevia Health Plc ("Eevia" or "The Company"), a leading health ingredient manufacturer from Finland, today announces that it has entered a multi-year sales agreement. The sales agreement is with a Finnish customer to supply a specialty protein and fiber plant extract with excellent nutritional values and versatile product applications for the global nutraceutical market. In addition, the customer has installed a specialty dryer in the Eevia Health plant. The investment was approximately EUR 300.000, which was funded by the customer. Eevia operates the machine, and after the fulfillment of sales volumes to the customer, Eevia Health can use this equipment free of charge.
The customer is a recognized leader in the food ingredient marketplace with a European footprint. The group has annual sales of approximately EUR 300 million in 2021 and offers plant-based food solutions for the European and global markets.
The customer will fund and organize the raw material purchase, thus shielding Eevia Health from changing raw material prices. The arrangement secures a significant gross margin contribution to the Company during the period. Management expects the first three years of the sales agreement to provide revenues for Eevia Health of SEK 8 million at very high gross margins. Eevia considers the potential for much faster growth than expected for the first three years and extensions after three years.
"This sales agreement is a welcome addition to our growing order reserve, especially because this is a circular economy product with a robust margin. As we have increased our green-chemistry manufacturing capacity during 2021, we are in 2022 driving to widen our long-term product and customer portfolio. The sales agreement demonstrates that we can compete with an efficient extraction platform based in Finland and is another step towards our turnover target of EUR 25 million in 2024.", says CEO Stein Ulve in Eevia Health.
This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on March 9, 2022.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency.
Eevia's headquarter is in Seinäjoki, Finland. As of the end of fourth-quarter 2021, the Company had 26 full-time employees. The total revenue for the full year ended December 31, 2021, was EUR 6.7 million up from EUR 2,8 million in 2021. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.
Analyst Group Initiates equity research Coverage of Eevia Health Plc, ("Eevia" or "The Company").
Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus.
Eevia Health Plc, ("Eevia" or "The Company"), has received a 21 KEUR sales order from its Australian distributor Ingredients Plus for a new product made from Lingonberry, after a new customer has decided to launch a new product with the Lingonberry ingredient as a key component.
Eevia Health Plc, ("Eevia" or "The Company"), has entered into an agreement whereby Exelity AB, Sweden will provide a credit line for Eevia of up to SEK 8 million, giving the Company increased working capital flexibility to finance its continued growth.
The Annual General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on June 21, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:
Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.
The shareholders of Eevia Health Abp, company registration number 2825194-4 in Finland, are hereby called for the Annual General Meeting (AGM) to be held on June 21st 2022.
Eevia Health Plc's (''Eevia'' or ''the Company'') Financial Statements for 2021 together with the Auditors' report have been published today.